Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Tremfya. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Guselkumab (sold as Tremfya), first approved Jul 13, 2017, with 9 new uses approved and 0 published complete response letters.
First approved: Jul 13, 2017
Applications: 1
New uses approved: 9
Complete response letters: 0
Medicare spending, 2025: $1.47B
First approved in the EU: Nov 10, 2017
First approved in Japan: Mar 23, 2018
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 8 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
TremfyaDrugs with a new indication and a new dosage for the remission induction therapy for moderate to severe ulcerative colitis (for use only in patients who… · Janssen Pharmaceutical K.K. · Feb 19, 2026
TremfyaDrugs with a new indication and a new dosage for the treatment of moderate to severe active Crohn's disease (for use only in patients who have not… · Janssen Pharmaceutical K.K. · Jun 24, 2025
Tremfya, new approval(1) A drug with a new route of administration indicated for the remission induction therapy for moderate to severe ulcerative colitis (for use only in… · Janssen Pharmaceutical K.K. · Mar 27, 2025
TremfyaA drug with a new additional indication for the treatment of palmoplantar pustulosis in patients who have not responded sufficiently to conventional therapies. · Janssen Pharmaceutical K.K. · Nov 21, 2018
Tremfya, new ingredientA drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in… · Janssen Pharmaceutical K.K. · Mar 23, 2018 · Review report
Clinical Trials
76 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA